News | November 01, 2021
Dr Reddys Laboratories posts Q2FY22 PAT at Rs 992 Cr
Dr. Reddy's Laboratories has reported consolidated financial results for the period ended September 30, 2021
Dr. Reddy's Laboratories has reported consolidated financial results for the period ended September 30, 2021
It is the first U.S. FDA approved novel topical mechanism for acne in nearly 40 years
The acquisition expands Takeda’s immuno-oncology and innate immune cell therapy portfolio with novel platforms leveraging T cells for the potential treatment of solid tumours and haematological malignancies
Its unique technology, ChetoSensar gives new promise to ADCs by alleviating solubility challenges
The collaboration provides KardiaMobile users quick access to doctors worldwide for consultations about their ECG readings
Two leaders in science combine complementary best-in-class technologies for biologics manufacturing customers
Acute therapies continue to report strong growth compared to chronic ones.
The youngest child in India to survive ECMO after undergoing bone marrow transplant for a rare disease
Following the review of around 20 candidate vaccines by the external advisory group, MVC's vaccine was selected as one of two to be included in the global trial
Subscribe To Our Newsletter & Stay Updated
